In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols

Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.

“…Indeed, in this study we found that the reduction of the cyclin D1 level was associated with a marked increase in chemosensitivity to cisplatinum in PANC-1 and COLO-357 cells. The in vivo achievable cisplatinum concentration that is not associated with significant clinical toxicity during an infusion time of 60 min in humans is at or below 10 g/ml (32). When these conditions were recapitulated in vitro in the present study, cisplatinum significantly inhibited the growth of the antisense expressing clones, whereas no effects were observed in cells with normal cyclin D1 levels.…”

Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer

“…1b and 2b) is a well known phenomenon 36. Heterogeneous response to the ongoing treatment is not unexpected among different subregions within the same tumor 37 and can be critically influenced by regional variations in blood supply and hypoxia 26,28,38. The pixel SI histogram analysis developed in our study (Figs.…”

“…The adverse effect of low tumor perfusion has been suggested by the association of large intercapillary distances with tumor recurrence 14. Similarly, it is well known that the success of chemotherapy in cervical cancer is critically influenced by the effectiveness of vascular delivery of therapeutic agents into the interstitial space within the heterogeneous tumor 28,29 Both, adequate delivery of oxygen and chemotherapy agents depend on tumor blood supply and on the ability to extravasate the oxygen and chemotherapeutic agents through the vessel wall into the interstitial space and to the tumor cell.…”

Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy

“…Because most of these patients receive an intraarterial port catheter system for arterial drug infusion before the start of therapy, tumor tissue can be obtained in approximately 50% of these patients during the implantation procedure without substantially expanding the scope of surgery. A part of the tumor tissue is used for in vitro chemosensitivity testing using the HTCA 25. In cases in which agents other than NOV or MMC showed higher in vitro cytotoxicity, HAI therapy was altered according to the in vitro test result independent of the primary tumor type 9, 15, 25…”

“…A part of the tumor tissue is used for in vitro chemosensitivity testing using the HTCA 25. In cases in which agents other than NOV or MMC showed higher in vitro cytotoxicity, HAI therapy was altered according to the in vitro test result independent of the primary tumor type 9, 15, 25…”